Nexara Health — Health Canada Drug Establishment Licence #3-002896

HANZEMA 30 MG

Last verified 2026-09-09 · Source: Health Canada Drug Product Database (DPD), DIN 02477440

HANZEMA 30 MG

ALITRETINOIN : 30 MG · DIN 02477440 · DR. REDDY'S LABORATORIES INC

Health Canada status: MARKETED

What is HANZEMA?

HANZEMA 30 MG contains ALITRETINOIN : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02477440, held by DR. REDDY'S LABORATORIES INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is HANZEMA used for?

Treatment of severe chronic hand eczema refractory to high potency topical corticosteroids in adults.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02477440
Brand nameHANZEMA
Generic / active ingredientALITRETINOIN : 30 MG
ManufacturerDR. REDDY'S LABORATORIES INC
Strength30 MG
Dosage formCAPSULE
Route of administrationORAL
SchedulePrescription
ATC codeD11AH04 ALITRETINOIN
AHFS class84:92.00
BiosimilarNo
Health Canada statusMARKETED
Status date09-Jun-2021
Original market date2021-06-09 00:00:00

How is it administered?

Oral administration. Treatment should only be prescribed by physicians knowledgeable in systemic retinoids. Prescriptions for women of childbearing potential are limited to 30 days.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Not explicitly detailed in the provided text (Summary Product Information section).

How is it supplied?

Not explicitly detailed in the provided text (mentions 10 mg and 30 mg strengths).

Contraindications

Pregnancy; breastfeeding; hepatic/severe renal insufficiency; uncontrolled hypercholesterolemia/hypertriglyceridemia; uncontrolled hypothyroidism; hypervitaminosis A; hypersensitivity to retinoids.

Warnings and precautions

Serious risk of teratogenicity. Associated with benign intracranial hypertension, depression/suicidal ideation, inflammatory bowel disease, and increased lipids. Avoid excessive UV exposure.

What can be used instead?

Other Canadian products sharing ATC code D11AH04 ALITRETINOIN. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
HANZEMA10 MGCAPSULEDR. REDDY'S LABORATORIES INCMARKETEDDIN 02477432
PANRETIN0.1 %GELLIGAND PHARMACEUTICALS INCCANCELLED (UNRETURNED ANNUAL)DIN 02240328
TOCTINO10 MGCAPSULEGLAXOSMITHKLINE INCCANCELLED POST MARKETDIN 02337630
TOCTINO30 MGCAPSULEGLAXOSMITHKLINE INCCANCELLED POST MARKETDIN 02337649

Who else supplies ALITRETINOIN worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. ALITRETINOIN appears in 8 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for HANZEMA

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Related pages

Sourcing this product